SG Americas Securities LLC Acquires Shares of 15,800 Pyxis Oncology, Inc. (NASDAQ:PYXS)

SG Americas Securities LLC acquired a new position in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 15,800 shares of the company’s stock, valued at approximately $58,000.

Several other institutional investors and hedge funds also recently modified their holdings of PYXS. StemPoint Capital LP acquired a new position in Pyxis Oncology during the 1st quarter worth approximately $7,643,000. Ikarian Capital LLC purchased a new position in shares of Pyxis Oncology in the first quarter valued at $7,082,000. Vanguard Group Inc. grew its holdings in Pyxis Oncology by 7.3% during the 1st quarter. Vanguard Group Inc. now owns 1,401,425 shares of the company’s stock valued at $5,970,000 after purchasing an additional 94,740 shares in the last quarter. Millennium Management LLC increased its stake in Pyxis Oncology by 125.3% during the 2nd quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock worth $4,425,000 after buying an additional 743,499 shares during the period. Finally, Blue Owl Capital Holdings LP acquired a new position in Pyxis Oncology in the 2nd quarter worth $3,462,000. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Stock Up 3.6 %

Shares of NASDAQ PYXS opened at $3.79 on Tuesday. The stock’s 50 day moving average price is $3.57 and its two-hundred day moving average price is $3.69. Pyxis Oncology, Inc. has a 52-week low of $1.35 and a 52-week high of $6.85. The stock has a market capitalization of $225.20 million, a P/E ratio of -3.06 and a beta of 1.27.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.04. On average, analysts anticipate that Pyxis Oncology, Inc. will post -1.04 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Pyxis Oncology in a research note on Friday, August 16th. Stifel Nicolaus assumed coverage on Pyxis Oncology in a research note on Thursday, August 8th. They set a “buy” rating and a $10.00 price objective for the company. Finally, Royal Bank of Canada restated an “outperform” rating and set a $7.00 price objective on shares of Pyxis Oncology in a report on Thursday, September 19th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $9.00.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.